Creating a faster and easier way to produce custom antibodies using machine learning.
Making antibody generation rapid, scalable, and democratic through machine learning and continuous evolution
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA-IRVINE · NIH-10898873
This study is working on a new way to quickly and easily create high-quality antibodies using special yeast cells and smart technology, which could help make better and more affordable treatments for patients, especially those with cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA-IRVINE (nih funded) |
| Locations | 1 site (IRVINE, UNITED STATES) |
| Trial ID | NIH-10898873 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new system called AEGYS that allows for the rapid and scalable production of high-quality antibodies. By using machine learning algorithms and a specially engineered yeast cell system, researchers aim to simplify the process of generating custom antibodies, which are essential for various biomedical applications, including cancer therapy. Patients may benefit from this research as it could lead to more accessible and effective antibody-based treatments. The approach involves culturing yeast cells that can evolve to produce antibodies against specific antigens, making it a more efficient alternative to traditional methods.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals requiring personalized antibody treatments for conditions like cancer.
Not a fit: Patients who do not require antibody-based therapies or have conditions unrelated to antibody treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly enhance the availability and effectiveness of antibody-based therapies for patients.
How similar studies have performed: Other research has shown promise in using machine learning and novel techniques for antibody production, indicating a potential for success in this innovative approach.
Where this research is happening
IRVINE, UNITED STATES
- UNIVERSITY OF CALIFORNIA-IRVINE — IRVINE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIU, CHANG C — UNIVERSITY OF CALIFORNIA-IRVINE
- Study coordinator: LIU, CHANG C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.